Day: July 13, 2022

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, announces that, as previously disclosed pursuant to a Form 8-K filed with the Securities Exchange Commission on June 21, 2022, the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”) notifying it that the closing bid price of the Company’s common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following...

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) — Icanic Brands Company Inc. (“Icanic” or the “Company”) (CSE: ICAN) announced today that the Supreme Court of British Columbia (the “Court”) has issued an interim order (the “Interim Order”) authorizing, among other things, the holding of a meeting (the “Meeting”) of holders (the “Secured Debentureholders”) of 9.00% secured convertible debentures (the “2019 Debentures”), to consider and vote upon a plan of arrangement (the “Plan of Arrangement”) to implement the previously-announced recapitalization transaction (the “Recapitalization Transaction”). The 2019 Debentures have been issued pursuant to a convertible debenture indenture dated June 6, 2019 (the “2019 Debenture Indenture”) between LEEF Holdings, Inc. (“LEEF”) and Odyssey Trust Company (“Odyssey”), as trustee and...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 16,666,667 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to 16,666,667 shares of common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrant, less underwriting discounts and commissions. The warrants have an exercise price of $0.60 per share,...

GEORGE TOWN, Grand Cayman, July 12, 2022 (GLOBE NEWSWIRE) — O2Micro® International Limited (NASDAQ: OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, will announce its financial results for the Second Quarter ending June 30, 2022, on Friday July 29, 2022. The press release will be followed by a conference call at 6:00 a.m. (US Pacific), 9:00 a.m. (US Eastern). You may participate using the following dial-in information: Participants, Int’l Toll: 1-412-317-6060Participants, US/CAN: 1-866-652-5200 A live webcast will also be available on the Company’s website at http://ir.o2micro.com, and an online replay will be available on the website for one week. The Call-in Audio Replay will be available following the call from July 29, 2022, at 12:00PM Eastern...

New York, NY, July 12, 2022 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ:GFAI, GFAIW), an integrated security solutions provider, announced today that it has entered into agreements with several accredited investors that are existing holders of its private warrants, wherein the investors agreed to exercise 5,581,918 outstanding warrants (the “Existing Warrants”) to purchase an aggregate of 5,581,918 ordinary shares for cash, at an exercise price reduced by the Company from $1.15 per share to $0.238 per share. In consideration for the immediate exercise of the Existing Warrants for cash, the Company will issue one-half (1/2) of an ordinary share (the “Share Consideration”) for each warrant exercise. As a result, the exercising holders will receive approximately 2,790,959 ordinary shares....

Hong Kong, July 12, 2022 (GLOBE NEWSWIRE) — Intelligent Living Application Group Inc. (the “Company” or “Intelligent Living”), a premium lockset manufacturer in Hong Kong, today announced the pricing of its initial public offering (the “Offering”) of 5,060,000 ordinary shares at a price of $4.00 per share. The ordinary shares have been approved for listing on The Nasdaq Capital Market and are expected to commence trading on July 13, 2022 under the ticker symbol “ILAG.” The aggregate gross proceeds from the Offering will be $20.24 million, before deducting underwriting discounts and other related expenses. The Offering is expected to close on or about July 15, 2022, subject to the satisfaction of customary closing conditions. The Offering is being conducted on a firm commitment basis. Network 1 Financial Securities, Inc. is acting...

— 49% ORR amongst SAVANNAH patients with higher MET levels — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (“WCLC”), taking place August 6-9 in Vienna, Austria. SAVANNAH is a global Phase II study of HUTCHMED and AstraZeneca’s (LSE/​STO/​Nasdaq:​AZN) savolitinib in combination with AstraZeneca’s TAGRISSO® (osimertinib) in epidermal growth factor receptor (“EGFR”)-mutated non-small cell lung cancer (“NSCLC”) patients with mesenchymal epithelial transition receptor (“MET”) driven tumors, following disease progression...